
Question: if an mHSPC patient has a PSA decline on primary treatment to <0.2ng/mL, does the volume of metastases at diagnosis make a difference? Answer in our latest STAMPEDE trial manuscript eur01.safelinks.protection.o…
✓Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.

Question: if an mHSPC patient has a PSA decline on primary treatment to <0.2ng/mL, does the volume of metastases at diagnosis make a difference? Answer in our latest STAMPEDE trial manuscript eur01.safelinks.protection.o…

How can we prevent the aggressive disease course of PTEN loss/inactive cancers? @EmilyGrist1 @ChrisSweens1 eur01.safelinks.protection.o…

About time! Good news for those men currently paying out of pocket for Abiraterone and great news for all men who will benefit in future. Well done @ProstateUK for your relentless campaigning to right this wrong.

Quick overview of news in Prostate Cancer from Esmo with @Ecastromarcos @AttardLab and Axel Heidenreich Please follow ecancer.org/en/video/12526-b…

🚨 Big News from #APCCC26 🚨 APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer! Full details & submission 👉 apccc.org 📅 Key Dates: 🔹 Submission opens: 1 Sept 2025 🔹 Deadline: 14 Nov 2025, 23:59 CET 🔹 Notifications: 19 Dec 2025 ✅ Complimentary registration for presenting authors. ✅ Travel grants available for LMIC investigators. ✅ Selected abstracts will be presented as posters in Lugano (30 Apr–1 May 2026). Categories: Advanced prostate cancer Side effects & QoL/PROs Global access to therapies @Silke_Gillessen & @AOmlin @OncoAlert 🚨 @fabioturco92 @Prof_IanD @drjefstathiou @Prof_Nick_James @ChrisSweens1 @BertrandTOMBAL @ZilliThomas @neerajaiims @bjartell @PBlanchardMD @BourlonMaite @Albert0Briganti @cdanicas @Ecastromarcos @mdesantis234 @nachoduranm @drlouiseemmett @stefanofanti4 @fontev1 @Nicola_Fossati @marty_gleave @ProfKHerrmann @DrMHofman @BarbaraJereczek @ravikanesvaran @FacsRaja @LoebStacy @quimmateo @DrRanaMcKay @amerseburger @CaPsurvivorship @declangmurphy @DrPaulNguyen @WilliamOhMD @piet_ost @DrSpratticus @cnsternberg @DrYukselUrun @DrChoueiri @tompowles1 @brian_rini Ping @nataliagandur @bavilima @yekeduz_emre

The mHSPC space becomes more and more interesting! Come and participate in the discussions @APCCC_Lugano register via apccc.org!

@AzadOncology asking the question- do all patients need six cycles of Lu-PSMA in #PSMAaddition? Showing a nice example of complete response after two cycles on #UpFrontPSMA

CAPItello-281 In de novo PTEN-deficient mHSPC (poor prognosis), capivasertib + abiraterone ↑ rPFS vs pbo + abiraterone (33.2 vs 25.7 mo; HR 0.81; P=0.034), OS immature. ↑ PTEN loss correlated with ↑ benefit; POTENTIAL for now With Amplitude trial paving the way, NGS is key in mHSPC How should we integrate this combo when triplet is already available? @OncoAlert @myESMO #ESMO25

Publication of CAPItello-281 Ph 3 trial in @Annals_Oncology at end of @fizazi_karim #ESMO25 👍annalsofoncology.org/article…

Wonderful discussion by @Prof_Nick_James on EnzaRad highlighting the differences between Stampede. Lower risk group enrolled and differential effect of ARPI in higher risk group. #ESMO25 @myESMO @OncoAlert

EnzaRad P3 trial confirms boundary of patient benefit sits somewhere between STAMPEDE ultra HR and NCCN HR. Working together we will use BM to define this #ESMO25

#ESMO25 #challengeYourExpert @AttardLab @UrsulaVogl @myESMO #ProstateCancer


STAMPEDE update at #ESMO25today at noon. Landmark analysis of 7,129 pts shows PSA ≤0.2 ng/mL by 6–12 weeks strongly predicts OS in HSPC. Prognostic value modified by metastatic volume & nodal status. Abiraterone ± enzalutamide delivers deepest PSA responses & best survival.

ALBAN #ESMO25 (atezolizumab/BCG vs BCG in MIBC) @Annals_Oncology did not ⬆️ EFS (HR0.97) unlike sasalimab & durvalumab in a similar setting. The drugs seem similar in metastatic UC so was it trial design making it different from other ICIs? EFS was defined differently.

🧪Sequential liquid biopsies reveal ctDNA features and dynamics linked to survival & resistance in advanced #ProstateCancer patients treated with cabazitaxel. 🧬 cell cycle gene amplification associates with taxane resistance 🤝Results from an international collaborative effort